EZH2 inhibitors downregulate the level of ChK1 phosphorylation through an unknown mechanism, thereby inhibiting the DNA damage response (Wu et al., 2011), and ChK1 inhibitors are more sensitive in EZH2-deficient tumor cells, more apparently inducing cell apoptosis (Leon et al., 2020). Here, EZH2 is linked to neoplasm.